Michael Hudecek

Medizinische Klinik und Poliklinik II und Lehrstuhl für Zelluläre Immuntherapie, Universitätsklinikum Würzburg

Affiliated withUniversitätsklinikum Würzburg Außenstelle Würzburg Zelluläre Immuntherapie Fraunhofer Institut für Zelltherapie und Immunologie (IZI)

Research Area

Biography

Michael Hudecek has not added Biography.
If you are Michael Hudecek and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 3	Year
Publication title Cited by 7	2024
Publication title	2026
Publication title	2026

Other Publications

Article	Year
Myeloma CARs are rolling into the clinical arena. Blood\| PubMed ID: 27688779	2016
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. The Journal of clinical investigation\| PubMed ID: 27760047	2016
Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer\| PubMed ID: 28101686	2016
Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side. Critical reviews in biochemistry and molecular biology\| PubMed ID: 28402189	2017
Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. Blood\| PubMed ID: 28476749	2017
Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility. Journal of molecular biology\| PubMed ID: 28818634	2017
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7 normal lymphocytes. Blood\| PubMed ID: 29089311	2017
CAR T-cells targeting FLT3 have potent activity against FLT3ITD AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia\| PubMed ID: 29472720	2018
Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia. Current research in translational medicine\| PubMed ID: 29655962	2018
CARs and other T cell therapies for MM: The clinical experience. Best practice & research. Clinical haematology\| PubMed ID: 29909915	2018
Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system. Current opinion in genetics & development\| PubMed ID: 29957586	2018
CAR T cells targeting αβ integrin are effective against advanced cancer in preclinical models. Advances in cell and gene therapy\| PubMed ID: 30420973	2018
Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 30573301	2019
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the Ame... Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation\| PubMed ID: 30576834	2019
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantatio... Bone marrow transplantation\| PubMed ID: 31092900	2019
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Science translational medicine\| PubMed ID: 31270272	2019
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nature communications\| PubMed ID: 31316055	2019
ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI insight\| PubMed ID: 31415244	2019
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood\| PubMed ID: 31558469	2019
A highly soluble Sleeping Beauty transposase improves control of gene insertion. Nature biotechnology\| PubMed ID: 31685959	2019
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and t... Haematologica\| PubMed ID: 31753925	2020
Antibody-Based CAR T Cells Produced by Lentiviral Transduction. Current protocols in immunology\| PubMed ID: 32150338	2020
β-. Journal for immunotherapy of cancer\| PubMed ID: 32303620	2020
Chemically Programmable and Switchable CAR-T Therapy. Angewandte Chemie (International ed. in English)\| PubMed ID: 32329959	2020
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia\| PubMed ID: 32350373	2021
Inefficient CAR-proximal signaling blunts antigen sensitivity. Nature immunology\| PubMed ID: 32632291	2020
New targets and technologies for CAR-T cells. Current opinion in oncology\| PubMed ID: 32657796	2020
What is the future of immunotherapy in multiple myeloma? Blood\| PubMed ID: 32735639	2020
Overcoming key challenges in cancer immunotherapy with engineered T cells. Current opinion in oncology\| PubMed ID: 32796230	2020
Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies. HemaSphere\| PubMed ID: 32904089	2020
BATF3 programs CD8 T cell memory. Nature immunology\| PubMed ID: 32989328	2020
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. Advanced drug delivery reviews\| PubMed ID: 33798643	2021
Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 33940156	2021
Microbial short-chain fatty acids modulate CD8 T cell responses and improve adoptive immunotherapy for cancer. Nature communications\| PubMed ID: 34210970	2021
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood\| PubMed ID: 34289026	2021
T-Cell Metabolism in Graft Host Disease. Frontiers in immunology\| PubMed ID: 34777373	2021
Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia\| PubMed ID: 34845317	2022
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia. Cancers\| PubMed ID: 34944782	2021
CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism. Theranostics\| PubMed ID: 35198053	2022
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. Journal for immunotherapy of cancer\| PubMed ID: 35577500	2022
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside? Journal for immunotherapy of cancer\| PubMed ID: 35577501	2022
The era of in vivo T cell engineering. Med (New York, N.Y.)\| PubMed ID: 35590210	2022
Toward Rapid, Widely Available Autologous CAR-T Cell Therapy - Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital. Frontiers in medicine\| PubMed ID: 35733863	2022
Highjacking myeloma's niche with beefed-up CAR-Ts. Blood\| PubMed ID: 35771562	2022
ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene\| PubMed ID: 35859167	2022
Automated, scaled, transposon-based production of CAR T cells. Journal for immunotherapy of cancer\| PubMed ID: 36096530	2022
CAR T cells targeting are effective at treating invasive pulmonary aspergillosis in preclinical models. Science translational medicine\| PubMed ID: 36170447	2022
Engineering CD20 CARs with a Twist. Cancer immunology research\| PubMed ID: 36633575	2023
All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells. Haematologica\| PubMed ID: 36722406	2023
Genome Editing in Engineered T Cells for Cancer Immunotherapy. Human gene therapy\| PubMed ID: 37694593	2023
Learning from the microbes: exploiting the microbiome to enforce T cell immunotherapy. Frontiers in immunology\| PubMed ID: 37799719	2023
BCMA CAR-T cells in multiple myeloma-ready for take-off? Leukemia & lymphoma\| PubMed ID: 37997705	2024
CAR T-cell therapy in multiple myeloma: mission accomplished? Blood\| PubMed ID: 38033289	2024
Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations. Frontiers in immunology\| PubMed ID: 38077331	2023
Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Frontiers in immunology\| PubMed ID: 38187393	2023
Trust in and Acceptance of Artificial Intelligence Applications in Medicine: Mixed Methods Study. JMIR human factors\| PubMed ID: 38231544	2024
Mutation-specific CAR T cells as precision therapy for IGLV3-21 expressing high-risk chronic lymphocytic leukemia. Nature communications\| PubMed ID: 38307904	2024
Correction: ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene\| PubMed ID: 38383728	2024
Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells. Cell stem cell\| PubMed ID: 38754430	2024
Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features. Cellular oncology (Dordrecht, Netherlands)\| PubMed ID: 39192092	2024
CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation. Journal for immunotherapy of cancer\| PubMed ID: 33127653	2020
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. Annals of hematology\| PubMed ID: 33575947	2021
Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway. Cancer immunology, immunotherapy : CII\| PubMed ID: 37052701	2023
TCR/CD3-based synthetic antigen receptors (TCC) convey superior antigen sensitivity combined with high fidelity of activation. Science advances\| PubMed ID: 39231214	2024
Metabolization of microbial postbiotic pentanoate drives anti-cancer CAR T cells. bioRxiv : the preprint server for biology\| PubMed ID: 39314273	2025
Optimizing CAR-T treatment: A TEVOLVE guide to raw and starting material selection. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 39533710	2025
Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy\| PubMed ID: 39589646	2025
Cellular Therapies for Multiple Myeloma: Engineering Hope. Cancers\| PubMed ID: 39594822	2024
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept. Journal of immunotoxicology\| PubMed ID: 39655500	2024
Current Non-Viral-Based Strategies to Manufacture CAR-T Cells. International journal of molecular sciences\| PubMed ID: 39769449	2024
Short-Chain Fatty Acids Modulate Anti-ROR1 CAR T-Cell Function and Exhaustion in an Intestinal Adenocarcinoma-on-Chip Model. Advanced healthcare materials\| PubMed ID: 40249196	2025
European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring. Frontiers in immunology\| PubMed ID: 40342422	2025
Impact of Serum/Xeno-Free Medium and Cytokine Supplementation on CAR-T Cell Therapy Manufacturing in Stirred Tank Bioreactors. Biotechnology journal\| PubMed ID: 40923846	2025
Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities. Nature reviews. Clinical oncology\| PubMed ID: 40973826	2025
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe. Blood advances\| PubMed ID: 40991391	2025
ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. Cell reports. Medicine\| PubMed ID: 41056951	2025
Fine tuning towards the next generation of engineered T cells. Nature biomedical engineering\| PubMed ID: 41073806	2025
Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe. Cytotherapy\| PubMed ID: 41217312	2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy. HemaSphere\| PubMed ID: 41368079	2025
Current capacity and gaps in viral vector manufacturing: a survey of centers associated with CTIWP of EBMT, NXTGEN-hightech, DARE-NL, T2EVOLVE, and GoCART coalition. Bone marrow transplantation\| PubMed ID: 41408458	2026
The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies. HemaSphere\| PubMed ID: 41799248	2026